Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CFO | March 03, 2022 | March 04, 2022 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director · Interim CFO | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date March 03, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,819 |
Ending reported balance
After 2022-03-03 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2022-03-03 · Exercise / conversion · Acquired 3,846 · Balance 29,665 Row 2 · 2022-03-03 · Exercise / conversion · Acquired 3,304 · Balance 32,969 Row 3 · 2022-03-03 · Exercise / conversion · Acquired 1,815 · Balance 34,784 Row 4 · 2022-03-03 · Sale · Disposed 3,825 · Balance 30,959 F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2022-03-03 · Sale · Disposed 2,606 · Balance 28,353 F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2022-03-03 · Sale · Disposed 1,289 · Balance 27,064 F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2022-03-03 · Sale · Disposed 858 · Balance 26,206 F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2022-03-03 · Sale · Disposed 387 · Balance 25,819 F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.34 · Expires 2023-02-23 | Direct | 0 |
Reported balance
After 2022-03-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-03 · Exercise / conversion · Disposed 3,846 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $144.67 · Expires 2024-02-22 | Direct | 3,305 |
Reported balance
After 2022-03-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-03-03 · Exercise / conversion · Disposed 3,304 · Balance 3,305 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.66 · Expires 2030-05-29 | Direct | 5,446 |
Reported balance
After 2022-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-03-03 · Exercise / conversion · Disposed 1,815 · Balance 5,446 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $280.98 to $281.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $281.98 to $282.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $283.00 to $283.7. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $284.28 to $284.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $285.09 to $285.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Fortrea Holdings Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 28,692 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 15,840 · Balance 28,692 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service. F3: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock").
F2: Represents a RSU award that vests in its entirety twelve months after August 03, 2026, subject to the Reporting Person's continued service.
F3: This number reflects the aggregate number of RSUs held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2021 Filed Feb 23, 2021 16:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,149 | $292.37 | $335,937.15 |
DisclosureSEC source: 0001127602-21-007205 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F3 · price: This transaction was executed in multiple trades at prices ranging from $292.02 to $292.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 16:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,400 | $291.83 | $408,557.94 |
DisclosureSEC source: 0001127602-21-007205 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,149 F2 · price: This transaction was executed in multiple trades at prices ranging from $291.28 to $291.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 16:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,107 | $290.03 | $1,771,190.61 |
DisclosureSEC source: 0001127602-21-007205 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,549 F1 · price: This transaction was executed in multiple trades at prices ranging from $290.00 to $290.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,795 | $260.88 | $990,039.60 |
DisclosureSEC source: 0001127602-21-003421 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 14,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003421 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,345 F2 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 23, 2018. Read SEC document |
| January 25, 2021 Filed Feb 2, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 8,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003421 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 8,656 Read SEC document |
| January 25, 2021 Filed Feb 2, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 8,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003421 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,111 F1 · shares: On 1/25/2021 8,656 shares were gifted to Mr. Smith's spouse. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 111 | $254.77 | $28,279.78 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 12 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,767 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F13 · price: This transaction was executed in multiple trades at prices ranging from $254.62 to $254.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 310 | $253.88 | $78,703.64 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 11 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,878 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F12 · price: This transaction was executed in multiple trades at prices ranging from $253.41 to $253.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 303 | $252.99 | $76,656.15 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 10 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,188 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $252.57 to $253.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 426 | $251.90 | $107,310.72 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 9 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,491 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $251.50 to $252.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 133 | $250.87 | $33,365.22 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 8 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,917 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $250.8 to $250.87 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 531 | $249.97 | $132,734.18 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,050 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $249.46 to $250.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 935 | $248.84 | $232,661.57 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,581 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $248.49 to $249.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 756 | $247.89 | $187,406.43 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,516 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $247.41 to $248.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 535 | $246.76 | $132,017.40 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,272 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $246.39 to $247.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 264 | $245.57 | $64,830.19 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,807 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $245.46 to $246.195. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 165 | $244.94 | $40,415.58 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,071 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $244.69 to $245.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 531 | $243.71 | $129,407.57 |
DisclosureSEC source: 0001127602-21-000746 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,236 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $243.365 to $244.265. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,304 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-20-023248 · form4.xml · derivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,914 Underlying: Common Stock · 3,304 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,007 | $216.82 | $218,334.22 |
DisclosureSEC source: 0001127602-20-023248 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,767 F2 · price: This transaction was executed in multiple trades at prices ranging from $216.72 to $216.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,297 | $216.42 | $497,109.62 |
DisclosureSEC source: 0001127602-20-023248 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,774 F1 · price: This transaction was executed in multiple trades at prices ranging from $215.72 to $216.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,304 | $144.67 | $477,989.68 |
DisclosureSEC source: 0001127602-20-023248 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 7,261 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-20-018386 · form4.xml · derivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,261 Underlying: Common Stock · 7,261 shares Expires 2030-05-29 F2 · shares: Stock Options vest as follows: 1,815 on May 29, 2021, 1,815 on May 29, 2022, 1,815 on May 29, 2023 and 1,816 on May 29, 2024, Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018386 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,767 F1 · shares: Unvested restricted stock units vest in one-fourth increments on May 29, 2021, 2022, 2023 and 2024. Read SEC document |
| May 07, 2020 Filed May 8, 2020 14:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,884 | $150.00 | $282,600.00 |
DisclosureSEC source: 0001127602-20-015882 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,591 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 17:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 379 | $162.46 | $61,572.34 |
DisclosureSEC source: 0001127602-20-007861 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,188 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · derivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,188 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 738 | $164.19 | $121,175.76 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $163.835 to $164.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 657 | $163.38 | $107,339.35 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,213 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $162.85 to $163.825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,027 | $162.27 | $166,653.55 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,870 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $161.98 to $162.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 898 | $161.58 | $145,094.80 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,897 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.125 to $161.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 868 | $160.45 | $139,271.38 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,795 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.87 to $160.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 19:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,188 | $73.70 | $308,655.60 |
DisclosureSEC source: 0001127602-20-008104 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 17:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 402 | $173.64 | $69,803.28 |
DisclosureSEC source: 0001127602-20-007128 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,854 Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,846 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · derivative · entry 7 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,691 Underlying: Common Stock · 3,846 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,365 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · derivative · entry 6 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,366 Underlying: Common Stock · 4,365 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 351 | $168.37 | $59,097.20 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · nonDerivative · entry 5 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,854 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $168.225 to $169.065. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 985 | $167.49 | $164,981.79 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · nonDerivative · entry 4 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,205 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $167.22 to $167.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,875 | $166.53 | $1,144,873.81 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · nonDerivative · entry 3 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,190 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $166.095 to $167.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,846 | $109.34 | $420,521.64 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 16:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,365 | $88.05 | $384,338.25 |
DisclosureSEC source: 0001127602-20-007487 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 17:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 378 | $173.64 | $65,635.92 |
DisclosureSEC source: 0001127602-20-007128 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,256 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 17:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 344 | $173.64 | $59,732.16 |
DisclosureSEC source: 0001127602-20-007128 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,634 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 00:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,500 | $170.29 | $766,318.50 |
DisclosureSEC source: 0001127602-20-005367 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,978 F1 · price: This transaction was executed in multiple trades at prices ranging from $169.925 to $170.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 5,031 | $159.07 | $800,281.17 |
DisclosureSEC source: 0001127602-20-004573 · form4.xml · nonDerivative · entry 2 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,478 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 13,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004573 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,509 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 24, 2017. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 19:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 337 | $132.60 | $44,686.20 |
DisclosureSEC source: 0001127602-19-026380 · form4.xml · nonDerivative · entry 1 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,078 Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 19:32 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,249 | $0.00 Strike: $76.12 | $0.00 |
DisclosureSEC source: 0001127602-19-026518 · form4.xml · derivative · entry 22 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,249 shares Expires 2020-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 19:32 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3 | $131.32 | $393.96 |
DisclosureSEC source: 0001127602-19-026518 · form4.xml · nonDerivative · entry 21 Smith David Ross · CIK 0001650274 · Corporate Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,078 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.